Epidemiology of Budd-Chiari syndrome

A systematic review and meta-analysis

Yingying Li, Valerio De Stefano, Hongyu Li, Kexing Zheng, Zhaohui Bai, Xiaozhong Guo, Xingshun Qi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background and aims: The global epidemiological data of Budd-Chiari syndrome (BCS) are scant. A systemic review and meta-analysis aimed to estimate the incidence and prevalence of BCS. Methods: PubMed, EMBASE, and Cochrane Library databases were searched. The Newcastle-Ottawa Scale was used to assess the study quality. The pooled incidence and prevalence of BCS with 95% confidence intervals (CIs) were calculated by using a random-effect model. The heterogeneity was assessed by the Cochran's Q-test and I2 statistics. Subgroup analysis was conducted based on the study region (Asia or Europe). Results: Overall, six studies were included. Among them, 2 studies were performed in Asian countries (i.e., Japan and South Korea) and 4 in European countries (i.e., Denmark, Sweden, Italy, and France). All of them were of high quality. The annual incidence of BCS was 0.168–4.09 per million. The prevalence of BCS was 2.40–33.10 per million. Meta-analyses showed that the pooled annual incidence of BCS was 1 per million (95% CI = 0.225–3 per million) and the pooled prevalence of BCS was 11 per million (95% CI = 4–21 per million). The heterogeneity among studies was statistically significant. Subgroup meta-analyses demonstrated that the pooled annual incidence of BCS was 0.469 per million in Asia and 2 per million in Europe and the pooled prevalence of BCS was 5 per million in Asia. Conclusion: Evidence from meta-analyses of existing literature confirmed that BCS should be a rare vascular liver disease. BCS may not be more common in Asia than Europe. More epidemiological data in other countries should be warranted.

Original languageEnglish
JournalClinics and Research in Hepatology and Gastroenterology
DOIs
Publication statusAccepted/In press - Jan 1 2018

Fingerprint

Budd-Chiari Syndrome
Meta-Analysis
Epidemiology
Incidence
Confidence Intervals
Republic of Korea
Denmark
Vascular Diseases
PubMed
Sweden
Italy
Libraries
France
Liver Diseases
Japan

Keywords

  • Budd-Chiari syndrome
  • Epidemiology
  • Incidence
  • Meta-analysis
  • Prevalence

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Epidemiology of Budd-Chiari syndrome : A systematic review and meta-analysis. / Li, Yingying; De Stefano, Valerio; Li, Hongyu; Zheng, Kexing; Bai, Zhaohui; Guo, Xiaozhong; Qi, Xingshun.

In: Clinics and Research in Hepatology and Gastroenterology, 01.01.2018.

Research output: Contribution to journalArticle

Li, Yingying ; De Stefano, Valerio ; Li, Hongyu ; Zheng, Kexing ; Bai, Zhaohui ; Guo, Xiaozhong ; Qi, Xingshun. / Epidemiology of Budd-Chiari syndrome : A systematic review and meta-analysis. In: Clinics and Research in Hepatology and Gastroenterology. 2018.
@article{376a6e6bafa247e4a94d3cf3fe870c50,
title = "Epidemiology of Budd-Chiari syndrome: A systematic review and meta-analysis",
abstract = "Background and aims: The global epidemiological data of Budd-Chiari syndrome (BCS) are scant. A systemic review and meta-analysis aimed to estimate the incidence and prevalence of BCS. Methods: PubMed, EMBASE, and Cochrane Library databases were searched. The Newcastle-Ottawa Scale was used to assess the study quality. The pooled incidence and prevalence of BCS with 95{\%} confidence intervals (CIs) were calculated by using a random-effect model. The heterogeneity was assessed by the Cochran's Q-test and I2 statistics. Subgroup analysis was conducted based on the study region (Asia or Europe). Results: Overall, six studies were included. Among them, 2 studies were performed in Asian countries (i.e., Japan and South Korea) and 4 in European countries (i.e., Denmark, Sweden, Italy, and France). All of them were of high quality. The annual incidence of BCS was 0.168–4.09 per million. The prevalence of BCS was 2.40–33.10 per million. Meta-analyses showed that the pooled annual incidence of BCS was 1 per million (95{\%} CI = 0.225–3 per million) and the pooled prevalence of BCS was 11 per million (95{\%} CI = 4–21 per million). The heterogeneity among studies was statistically significant. Subgroup meta-analyses demonstrated that the pooled annual incidence of BCS was 0.469 per million in Asia and 2 per million in Europe and the pooled prevalence of BCS was 5 per million in Asia. Conclusion: Evidence from meta-analyses of existing literature confirmed that BCS should be a rare vascular liver disease. BCS may not be more common in Asia than Europe. More epidemiological data in other countries should be warranted.",
keywords = "Budd-Chiari syndrome, Epidemiology, Incidence, Meta-analysis, Prevalence",
author = "Yingying Li and {De Stefano}, Valerio and Hongyu Li and Kexing Zheng and Zhaohui Bai and Xiaozhong Guo and Xingshun Qi",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.clinre.2018.10.014",
language = "English",
journal = "Clinics and Research in Hepatology and Gastroenterology",
issn = "2210-7401",
publisher = "Elsevier Masson",

}

TY - JOUR

T1 - Epidemiology of Budd-Chiari syndrome

T2 - A systematic review and meta-analysis

AU - Li, Yingying

AU - De Stefano, Valerio

AU - Li, Hongyu

AU - Zheng, Kexing

AU - Bai, Zhaohui

AU - Guo, Xiaozhong

AU - Qi, Xingshun

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background and aims: The global epidemiological data of Budd-Chiari syndrome (BCS) are scant. A systemic review and meta-analysis aimed to estimate the incidence and prevalence of BCS. Methods: PubMed, EMBASE, and Cochrane Library databases were searched. The Newcastle-Ottawa Scale was used to assess the study quality. The pooled incidence and prevalence of BCS with 95% confidence intervals (CIs) were calculated by using a random-effect model. The heterogeneity was assessed by the Cochran's Q-test and I2 statistics. Subgroup analysis was conducted based on the study region (Asia or Europe). Results: Overall, six studies were included. Among them, 2 studies were performed in Asian countries (i.e., Japan and South Korea) and 4 in European countries (i.e., Denmark, Sweden, Italy, and France). All of them were of high quality. The annual incidence of BCS was 0.168–4.09 per million. The prevalence of BCS was 2.40–33.10 per million. Meta-analyses showed that the pooled annual incidence of BCS was 1 per million (95% CI = 0.225–3 per million) and the pooled prevalence of BCS was 11 per million (95% CI = 4–21 per million). The heterogeneity among studies was statistically significant. Subgroup meta-analyses demonstrated that the pooled annual incidence of BCS was 0.469 per million in Asia and 2 per million in Europe and the pooled prevalence of BCS was 5 per million in Asia. Conclusion: Evidence from meta-analyses of existing literature confirmed that BCS should be a rare vascular liver disease. BCS may not be more common in Asia than Europe. More epidemiological data in other countries should be warranted.

AB - Background and aims: The global epidemiological data of Budd-Chiari syndrome (BCS) are scant. A systemic review and meta-analysis aimed to estimate the incidence and prevalence of BCS. Methods: PubMed, EMBASE, and Cochrane Library databases were searched. The Newcastle-Ottawa Scale was used to assess the study quality. The pooled incidence and prevalence of BCS with 95% confidence intervals (CIs) were calculated by using a random-effect model. The heterogeneity was assessed by the Cochran's Q-test and I2 statistics. Subgroup analysis was conducted based on the study region (Asia or Europe). Results: Overall, six studies were included. Among them, 2 studies were performed in Asian countries (i.e., Japan and South Korea) and 4 in European countries (i.e., Denmark, Sweden, Italy, and France). All of them were of high quality. The annual incidence of BCS was 0.168–4.09 per million. The prevalence of BCS was 2.40–33.10 per million. Meta-analyses showed that the pooled annual incidence of BCS was 1 per million (95% CI = 0.225–3 per million) and the pooled prevalence of BCS was 11 per million (95% CI = 4–21 per million). The heterogeneity among studies was statistically significant. Subgroup meta-analyses demonstrated that the pooled annual incidence of BCS was 0.469 per million in Asia and 2 per million in Europe and the pooled prevalence of BCS was 5 per million in Asia. Conclusion: Evidence from meta-analyses of existing literature confirmed that BCS should be a rare vascular liver disease. BCS may not be more common in Asia than Europe. More epidemiological data in other countries should be warranted.

KW - Budd-Chiari syndrome

KW - Epidemiology

KW - Incidence

KW - Meta-analysis

KW - Prevalence

UR - http://www.scopus.com/inward/record.url?scp=85057728354&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057728354&partnerID=8YFLogxK

U2 - 10.1016/j.clinre.2018.10.014

DO - 10.1016/j.clinre.2018.10.014

M3 - Article

JO - Clinics and Research in Hepatology and Gastroenterology

JF - Clinics and Research in Hepatology and Gastroenterology

SN - 2210-7401

ER -